SINGAPORE, Sept. 30, 2022 (GLOBE NEWSWIRE) — ALR Technologies Inc. (“ALRT”) (OTCQB: ALRT), the diabetes administration firm, is happy to announce an replace with respect to its migration to Singapore. Further to its Form 8-Okay filed May 20, 2022, and press launch issued May 20, 2022, the Registration Statement on Form F-4 filed by its affiliate, ALR Technologies SG Ltd. (“ALRT Singapore”), has been declared efficient by the Securities and Exchange Commission (the “SEC”). ALRT anticipates mailing the corresponding prospectus and knowledge assertion to its stockholders on or round October 4, 2022. ALRT expects to consummate the beforehand introduced reincorporation merger through which ALRT will grow to be an entirely owned subsidiary of ALRT Singapore as quickly as practicable following the required 20-day ready interval subsequent to mailing of the prospectus and knowledge assertion, topic to the satisfaction of customary closing situations, together with sure regulatory approvals from FINRA, the OTC Markets Group, ACRA (Singapore), and the Secretaries of State of Nevada and Delaware.
ALRT additional declares the proposed distribution settlement between ALRT Singapore and a number one animal well being firm for the commercialization of the GluCurve Pet CGM beforehand anticipated in September is now anticipated to be accomplished within the fourth quarter of 2022.
“We have a very strong relationship with both our hardware manufacturer and the leading animal health company we’re working with on a distribution agreement for the GluCurve. After much discussion and consideration, we have decided to push back the commercialization date to later in Q4,” defined Joe Stern, Head of Animal Health at ALRT and ALR Singapore. “The GluCurve production line is up and running, but our manufacturer has experienced delays before final testing can occur and our completed distribution agreement can be signed. During this time, we will continue to work closely with our planned partner on marketing content, strategy, and execution of the launch.”
Mr. Stern concludes, “We believe this extra time will contribute to a stronger and more successful launch in the coming months. We have universally received fantastic feedback on both the product and its need in the marketplace, and we look forward to providing more updates in the near future.”
About the GluCurve Pet CGM
The GluCurve Pet CGM is a Continuous Glucose Monitoring System for diabetic cats and canines, consisting of an Applicator, Sensor, Transmitter, GluCurve App, and Veterinary Web Portal.
The Sensor is situated contained in the Applicator and as soon as utilized to a pet, the Sensor Electrode chemically reacts with glucose within the hypodermic interstitial fluid to generate {an electrical} sign. The electrical sign is analyzed to generates blood glucose values, that are despatched to the GluCurve App the place it’s displayed for the pet proprietor and uploaded to the Veterinary Web Portal.
The GluCurve Pet CGM measures glucose ranges each 3 minutes for a complete of 480 readings every day, for up to 14 days. The monitor is supplied with inbuilt reminiscence that may retailer all 14 days of knowledge to stop the lack of readings when the pet proprietor is away from their pet. In addition, insulin injections and feeding instances will be enter into the GluCurve App which uploads the information to the Veterinary Web Portal. Inside the Veterinary Web Portal, glucose readings are organized into time saving graphs and tables with further options equivalent to glucose curve comparisons and overlays, insulin dose calculators, greatest observe pointers, and extra.
About ALR Technologies Inc.
ALRT is a knowledge administration firm that developed the ALRT Diabetes Solution, a complete strategy to diabetes care that features an FDA-cleared and HIPAA compliant diabetes administration system that collects information immediately from blood glucose meters and steady glucose monitoring units, and a patent pending Predictive A1C algorithm to observe therapy success between lab studies and an FDA-cleared Insulin Dosing Adjustment program. The total purpose is to optimize diabetes drug therapies to drive improved affected person outcomes.
In addition, the animal well being division of ALRT has developed the GluCurve Pet CGM, an answer to help veterinarians higher decide the efficacy of insulin therapies and to assist to establish the suitable dose and frequency of administration for companion animals, thereby delivering the identical optimization of diabetic drug therapies to pets as to people.
More details about ALRT will be discovered at www.alrt.com.
About ALR Technologies SG Ltd.
ALRT Singapore is an affiliate of ALRT and is in search of to commercialize the GluCurve Pet CGM. More Information concerning ALRT Singapore will be discovered at https://sg.alrt.com.
Cautionary Statement Regarding Forward-Looking Statements
Regarding ALRT Singapore
This information launch contains sure “forward-looking statements” as outlined below relevant securities laws. All info and statements contained herein that aren’t clearly historic in nature represent forward-looking statements and knowledge, and the phrases “anticipate”, “estimate”, “believe”, “continue”, “could”, “expect”, “intend”, “plan”, “postulates”, “predict”, “will”, “may” or comparable expressions suggesting future situations or occasions, or the damaging of those phrases, are usually meant to establish forward-looking info. Forward-looking statements are essentially primarily based upon a lot of estimates and assumptions that, whereas thought of affordable, are topic to recognized and unknown dangers, uncertainties, and different components which can trigger the precise outcomes and future occasions to differ materially from these expressed or implied by such forward-looking statements. Such dangers embrace all dangers and uncertainties expressed within the cautionary statements and threat components within the Registration Statement on Form F-4 filed by ALRT Singapore with the SEC on September 15, 2022, different dangers and uncertainties listed from time to time in paperwork filed with the SEC, and the next components: ALRT Singapore’s operation as a development-stage firm with restricted working historical past and a historical past of working losses; the necessity for substantial further funding to proceed the event of ALRT Singapore’s product candidates earlier than it might probably anticipate to grow to be worthwhile from gross sales of its merchandise and the chance that it might be unable to elevate further capital when wanted; the result of ALRT Singapore’s evaluate of strategic choices and of any motion that it might pursue on account of such evaluate; the prospect that ALRT Singapore might grow to be uncovered to pricey and damaging legal responsibility claims ensuing from the testing of its product candidates within the clinic or within the business stage; the prospect that ALRT Singapore’s scientific trials is probably not accomplished on schedule, or in any respect, on account of components equivalent to delayed enrollment or the identification of hostile results; uncertainty surrounding whether or not any of ALRT Singapore’s product candidates will obtain the regulatory approval obligatory for commercialization; if ALRT Singapore’s product candidates get hold of regulatory approval, its product candidates being topic to costly, ongoing obligations and continued regulatory overview; enacted and future laws might enhance the issue and value for ALRT Singapore to get hold of advertising and marketing approval and commercialization; dependence on governmental authorities and well being insurers establishing ample reimbursement ranges and pricing insurance policies; ALRT Singapore’s merchandise might not achieve market acceptance, through which case ALRT Singapore is probably not ready to generate product revenues; ALRT Singapore’s reliance on its present strategic relationships and the potential success or failure of strategic relationships, joint ventures or mergers and acquisitions transactions; ALRT Singapore’s reliance on third events to conduct its non-clinical and scientific trials and on third-party, single-source suppliers to provide or produce our product candidates; ALRT Singapore’s means to get hold of, keep and defend its mental property rights and function its business with out infringing or in any other case violating the mental property rights of others; ALRT Singapore’s means to adjust to the necessities below relevant mortgage amenities, together with reimbursement of quantities at present excellent and overdue, and quantities excellent when due; ALRT Singapore’s means to qualify for citation and stay on the OTCQB as a buying and selling marketplace for its widespread inventory; the prospect that sure intangible property associated to ALRT Singapore’s product candidates might be impaired; the prevalence of any occasion, change or different circumstances that would give rise to the appropriate of ALRT Singapore or ALRT to terminate the merger settlement; the result of any authorized proceedings that could be instituted in opposition to ALRT Singapore or ALRT; the failure to fulfill any of the remaining situations to the closing of or in any other case consummate the reincorporation merger on a well timed foundation or in any respect; the chance that the anticipated advantages of the reincorporation merger should not realized when anticipated or in any respect, together with on account of the influence of, or issues arising on account of the power of the economy and aggressive components within the areas the place ALRT Singapore and ALRT do business; the chance that the reincorporation merger could also be dearer to full than anticipated, together with on account of sudden components or occasions; diversion of administration’s consideration from ongoing business operations and alternatives; potential hostile reactions or modifications to business or worker relationships, together with these ensuing from the announcement or completion of the reincorporation merger. ALRT Singapore can provide no assurance that any purpose or plan or expectation set forth in forward-looking statements will be achieved and readers are cautioned not to place undue reliance on such statements. The forward-looking statements are made as of the date of this communication, and ALRT Singapore doesn’t intend, and assumes no obligation, to replace any forward-looking assertion to mirror occasions or circumstances after the date on which the assertion is made or to mirror the prevalence of unanticipated occasions or circumstances, besides as required by relevant legislation.
Regarding ALRT
With respect to ALRT, stockholders are cautioned that any forward-looking statements that relate to time durations earlier than the closing of the reincorporation merger, as recognized by the usage of phrases or phrases as famous above, together with statements concerning the anticipated timing of the closing of the reincorporation merger, are topic to dangers, assumptions and uncertainties which are troublesome to predict. Although ALRT believes that the expectations mirrored in these forward-looking statements are affordable as of the date made, precise outcomes might show to be materially completely different from the outcomes expressed or implied by the forward-looking statements. Such components embrace, with out limitation, the “Risk Factors” referenced in ALRT’s definitive info assertion associated to the reincorporation merger and filed with the SEC on September 29, 2022, and its different SEC filings, together with its Annual Reports on Form 10-Okay and Quarterly Reports on Form 10-Q, and the next components: the prevalence of any occasion, change or different circumstances that would give rise to the appropriate of ALRT Singapore or ALRT to terminate the merger settlement; the result of any authorized proceedings that could be instituted in opposition to ALRT Singapore or ALRT; and the failure to fulfill any of the remaining situations to the closing of the reincorporation merger on a well timed foundation or in any respect. The forward-looking statements are made as of the date of this communication, and ALRT doesn’t intend, and assumes no obligation, to replace any forward-looking assertion to mirror occasions or circumstances after the date on which the assertion is made or to mirror the prevalence of unanticipated occasions or circumstances, besides as required by relevant legislation.
Important Additional Information
This information launch is being made in respect of the pending reincorporation merger involving ALRT and ALRT Singapore. As described above, in reference to the pending reincorporation merger ALRT Singapore filed with the SEC a Registration Statement on Form F-4, which has been declared efficient by the SEC (the “Registration Statement”), which included a preliminary info assertion of ALRT and a prospectus of ALRT Singapore (the “Information Statement/Prospectus”). It is anticipated that the definitive Information Statement/Prospectus might be mailed or in any other case delivered to the stockholders of ALRT on or about October 4, 2022. Stockholders are urged to learn the Registration Statement and Information Statement/Prospectus and some other related paperwork filed with the SEC, in addition to any amendments or dietary supplements to these paperwork, as a result of they may include necessary info.
This communication shall not represent a proposal to promote or the solicitation of a proposal to purchase any securities nor shall there be any sale of securities in any jurisdiction through which such provide, solicitation or sale could be illegal prior to registration or qualification below the securities legal guidelines of such jurisdiction.
Stockholders are ready to get hold of a free copy of the Registration Statement and Information Statement/Prospectus, in addition to different filings containing details about ALRT and ALRT Singapore, with out cost, on the SEC’s web site (http://www.sec.gov). Copies of the Registration Statement and Information Statement/Prospectus and the filings with the SEC integrated by reference therein can be obtained, with out cost, by directing a request to ALR Technologies Inc., 7400 Beaufont Springs Drive, Suite 300, Richmond, Virginia 23225, Attention: Corporate Secretary.
Contact Information
ALR Technologies Inc.
Investor Contact
Email Investor Relations: [email protected]
Email Animal Health Inquiries: [email protected]
Phone US: +1 804 554 3500
Phone Singapore: +65 3129 2924
ALR Technologies SG Ltd.
Investor Contact
Email Investor Relations: [email protected]
Email Animal Health Inquiries: [email protected]
Phone US: +1 804 554 3500
Phone Singapore: +65 3129 2924
